Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 2, 2003, Pages 313-323

  Zapata, Agustin ^a   Gasior, Maciej ^a,c,d   Geter Douglass, Beth ^a   Tortella, Frank C ^b   Newman, Amy Hauck ^a   Witkin, Jeffrey M ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c MCLEAN HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Cocaine; Dextromethorphan; Locomotor activity; NMDA; PCP; Seizures; Sigma 1

Indexed keywords

6 [6 (4 HYDROXY 1 PIPERIDINYL)HEXYLOXY] 3 METHYLFLAVONE; COCAINE; DEXTROMETHORPHAN(METHOXY 17 METHYLMORPHINAN); DEXTRORPHAN; DIZOCILPINE; ION CHANNEL; LIGAND; MORPHINAN DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CENTRAL STIMULANT AGENT; CONVULSANT AGENT; DEXTROMETHORPHAN; DRUG DERIVATIVE; SIGMA OPIATE RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; CONVULSION; CORRELATION ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; MOTOR ACTIVITY;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONVULSANTS; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MOTOR ACTIVITY; PHENCYCLIDINE; RECEPTORS, SIGMA;

EID: 0037211971     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01000-6     Document Type: Article

References (45)

1. Albers G.W., Atkinson R.P., Kelley R.E., Rosenbaum D.M. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke. 26:1995;254-258.
2. Barat S.A., Abdel-Rahman M.S. Decreased cocaine- and lidocaine-induced seizure response by dextromethorphan and DNQX in rat. Brain Res. 756:1997;179-183.
3. Barnhart J.W. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol. Appl. Pharmacol. 55:1980;43-48.
4. Bespalov A.Y., Dravolina O.A., Zvartau E.E., Beardsley P.M., Balster R.L. Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. Eur. J. Pharmacol. 390:2000;303-311.
5. Brackett R.L., Pouw B., Blyden J.F., Nour M., Matsumoto R.R. Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology. 39:2000;407-418.
6. Derlet R.W., Albertson T.E. Anticonvulsant modification of cocaine-induced toxicity in the rat. Neuropharmacology. 29:1990;255-259.
7. Dodds A. Toxic psychosis due to dextromethorphan. Med. J. Aust. 2:1967;231.
8. Fleming P.M. Dependence on dextromethorphan hydrobromide. Br. Med. J. (Clin. Res. Ed.). 293:1986;597.
9. Franklin P.H., Murray T.F. High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol. Pharmacol. 41:1992;134-146.
10. Gauvin D.V., Vanecek S.A., Baird T.J., Vallett M., Briscoe R.J., Carl K.L.et al. The stimulus properties of two common over-the-counter drug mixtures: dextromethorphan+ephedrine and dextromethorphan+diphenhydramine. J. Psychopharmacol. 12:1998;84-92.
11. Geter-Douglass B., Witkin J.M. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology (Berl.). 146:1999;280-289.
12. Ginski M.J., Witkin J.M. Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology (Berl.). 114:1994;573-582.
13. Gorski J.C., Jones D.R., Wrighton S.A., Hall S.D. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 48:1994;173-182.
14. Hascoet M., Bourin M., Payeur R., Lombet A., Peglion J.L. Sigma ligand S14905 and locomotor activity in mice. Eur. Neuropsychopharmacol. 5:1995;481-489.
15. Karbon E.W., Abreu M.E., Erickson R.H., Kaiser C., Natalie K.J.J., Clissold D.B.et al. NPC 16377, a potent and selective sigma-ligand: I. Receptor binding, neurochemical and neuroendocrine profile. J. Pharmacol. Exp. Ther. 265:1993;866-875.
16. Karler R., Calder L.D. Excitatory amino acids and the actions of cocaine. Brain Res. 582:1992;143-146.
17. Kim H.C., Park B.K., Hong S.Y., Jhoo W.K. Dextromethorphan alters the reinforcing effect of cocaine in the rat. Methods Find. Exp. Clin. Pharmacol. 19:1997;627-631.
18. Klein M., Musacchio J.M. High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents. J. Pharmacol. Exp. Ther. 251:1989;207-215.
19. Klein M., Musacchio J.M. High-affinity dextromethorphan and (+)-3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J. Pharmacol. Exp. Ther. 260:1992;990-999.
20. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D.et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
21. Leppik I.E., Marienau K., Graves N.M., Rask C.A. MK-801 for epilepsy: a pilot study. Neurology. 38:1988;405.
22. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 95:1949;99-113.
23. Maj J., Rogoz Z., Skuza G., Mazela H. Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Eur. J. Pharmacol. 315:1996;235-243.
24. McCracken K.A., Bowen W.D., de Costa B.R., Matsumoto R.R. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine- induced toxicity and locomotor activity. Eur. J. Pharmacol. 370:1999;225-232.
25. McCracken K.A., Bowen W.D., Matsumoto R.R. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur. J. Pharmacol. 365:1999;35-38.
26. Menkel M., Terry P., Pontecorvo M., Katz J.L., Witkin J.M. Selective sigma ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 201:1991;251-252.
27. Mets B., Virag L. Lethal toxicity from equimolar infusions of cocaine and cocaine metabolites in conscious and anesthetized rats. Anesth. Analg. 81:1995;1033-1038.
28. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
29. Murray T.F., Leid M.E. Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci. 34:1984;1899-1911.
30. Newman A.H., Jamshed H.S., Izenwasser S., Heller B., Mattson M., Tortella F.C. Highly selective sigma1 ligands based on dextromethorphan. Med. Chem. Res. 6:1996;102-117.
31. Pellinen P., Honkakoski P., Stenback F., Niemitz M., Alhava E., Pelkonen O.et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur. J. Pharmacol. 270:1994;35-43.
32. Pulvirenti L., Balducci C., Koob G.F. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321:1997;279-283.
33. Ritz M.C., George F.R. Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors. Psychopharmacology (Berl.). 129:1997;299-310.
34. Rockhold R.W., Oden G., Ho I.K., Andrew M., Farley J.M. Glutamate receptor antagonists block cocaine-induced convulsions and death. Brain Res. Bull. 27:1991;721-723.
35. Seidleck B.K., Thurkauf A., Witkin J.M. Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs dizocilpine and carbamazepine. Pharmacol. Biochem. Behav. 47:1994;839-844.
36. Snyder S.H. Phencyclidine. Nature. 285:1980;355-356.
37. Tortella F.C., Pellicano M., Bowery N.G. Dextromethorphan and neuromodulation: old drug coughs up new activities [see comments]. Trends Pharmacol. Sci. 10:1989;501-507.
38. Tortella F.C., Robles L., Witkin J.M., Newman A.H. Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. J. Pharmacol. Exp. Ther. 268:1994;727-733.
39. Tortella F.C., Britton P., Williams A., Lu X.C., Newman A.H. Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. 291:1999;399-408.
40. Uzbay I.T., Wallis C.J., Lal H., Forster M.J. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Behav. Brain Res. 108:2000;57-61.
41. Witkin J.M. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 53:1993;L405-L410.
42. Witkin J.M., Tortella F.C. Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sci. 48:1991;L51-L56.
43. Witkin J.M., Terry P., Menkel M., Hickey P., Pontecorvo M., Ferkany J.et al. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. Exp. Ther. 266:1993;473-482.
44. Witkin J.M., Gasior M., Heifets B., Tortella F.C. Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. J. Pharmacol. Exp. Ther. 289:1999;703-711.
45. Wolf M.E., Xue C.J., White F.J., Dahlin S.L. MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens. Brain Res. 666:1994;223-231